Erasca
The SVP Biometrics will lead biometrics activities across all programs from IND-enabling to registration and launch, overseeing Biostatistics, Statistical Programming & Analysis, and Clinical Data Management. This role requires hands-on execution and oversight of internal and external staff, as well as representation on the leadership team and in cross-functional discussions.
Headquarters
San Diego, California, United States
Company Size
51-200 employees
Founded
2018
Erasca is a clinical-stage precision oncology company on a mission “to erase cancer,” focused on therapies that shut down the RAS/MAPK signaling cascade — one of the most commonly mutated cancer pathways. Its pipeline comprises targeted programs that attack the RAS/MAPK pathway at multiple nodes, with the goal of addressing cancers driven by these mutations (a pathway that affects roughly 5.5 million people worldwide each year). By developing precision small molecules and combination strategies, Erasca aims to deliver transformative treatments that improve outcomes across a broad range of devastating cancers.
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC), Argenx Se (ARGX) and Erasca (ERAS)
1 day ago
RAS buzz lifts Erasca | ApexOnco - Clinical Trials news and analysis
Jan 14, 2026
Erasca (NASDAQ: ERAS) narrows 2025 loss and funds runway into H2 2028
5 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Erasca.
127% above the average for this role
Erasca secures worldwide rights to RAS-targeting drug ERAS-0015 By Investing.com
3 days ago